APA (7th ed.) Citation

Windyga, J., Lissitchkov, T., Stasyshyn, O., Mamonov, V., Rusen, L., Lamas, J. L., . . . Abbuehl, B. E. (2014). Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: A prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level ≤2%) haemophilia B. Haemophilia : the official journal of the World Federation of Hemophilia, 20(1), 15-24. https://doi.org/10.1111/hae.12228

Chicago Style (17th ed.) Citation

Windyga, J., et al. "Pharmacokinetics, Efficacy and Safety of BAX326, a Novel Recombinant Factor IX: A Prospective, Controlled, Multicentre Phase I/III Study in Previously Treated Patients with Severe (FIX Level <1%) or Moderately Severe (FIX Level ≤2%) Haemophilia B." Haemophilia : The Official Journal of the World Federation of Hemophilia 20, no. 1 (2014): 15-24. https://doi.org/10.1111/hae.12228.

MLA (9th ed.) Citation

Windyga, J., et al. "Pharmacokinetics, Efficacy and Safety of BAX326, a Novel Recombinant Factor IX: A Prospective, Controlled, Multicentre Phase I/III Study in Previously Treated Patients with Severe (FIX Level <1%) or Moderately Severe (FIX Level ≤2%) Haemophilia B." Haemophilia : The Official Journal of the World Federation of Hemophilia, vol. 20, no. 1, 2014, pp. 15-24, https://doi.org/10.1111/hae.12228.